Microbix Biosystems Inc.

What does Microbix Biosystems do?
Microbix Biosystems manufactures biological products for the global diagnostics industry. The company produces antigens used by approximately 100 diagnostics manufacturers to develop infectious disease antibody tests, and quality assessment products (QAPs) that help clinical laboratories verify test accuracy. Microbix also develops Kinlytic urokinase, a biologic thrombolytic drug for dissolving blood clots.

Is Microbix Biosystems publicly traded?
Yes, Microbix Biosystems trades on the Toronto Stock Exchange under ticker MBX. The company also trades on the OTCQX Best Market in the United States under the symbol MBXBF. Microbix went public in 1992 and is headquartered in Mississauga, Ontario, Canada.

Who founded Microbix Biosystems?
Microbix was founded in 1984 by William J. (Bill) Gastle, a virologist who started the company with the sale of bacterial and cellular growth media to Canadian public health laboratories. Gastle led the company until his passing on September 6, 2023, in Edmonton, Alberta. He built Microbix from a small laboratory media supplier into a global life sciences company.

What is Kinlytic urokinase?
Kinlytic is Microbix's brand of urokinase, a biologic thrombolytic drug that dissolves blood clots. It was previously marketed in the United States as Abbokinase for over 20 years. Microbix signed an agreement in May 2023 with Sequel Pharma LLC to fund the return of Kinlytic to the US market, with approximately C$50 million in funding needed for relaunch. FDA re-approval is anticipated in approximately two to three years from 2023.

What were Microbix's FY2025 financial results?
Microbix reported FY2025 (fiscal year ended September 30, 2025) revenue of C$18.6 million, a 27% decrease from FY2024 revenue of C$25.4 million. The company recorded a net loss of C$2.2 million, compared to net income of C$3.5 million in FY2024. The decline resulted from reduced antigen sales to China, cancellation of a QAPs client program, and absence of Kinlytic license payments.

What is Microbix's relationship with Sequel Pharma?
Microbix signed a commercialization agreement with Sequel Pharma LLC in May 2023 to return Kinlytic urokinase to the US market. Sequel, funded by a private equity firm, provides the estimated C$50 million needed for FDA re-approval and relaunch. Microbix has received US$4.0 million from Sequel and expects further milestone and royalty payments following FDA re-approval.

How is Microbix recovering from its FY2025 setbacks?
In Q3 FY2026 (quarter ended June 30, 2026), Microbix reported 17% year-over-year sales growth, driven by gains in its antigen and quality assessment product businesses. Excluding its Chinese distributor, antigen sales increased 6% in H1 FY2026. The company is working to add new client programs and clients to diversify its revenue base and reduce concentration risk.

Microbix was founded in 1984 by William J. (Bill) Gastle, a virologist who trained in the field and started the company with the sale of bacterial and cellular growth media to Canadian public health laboratories. The company was soon entrusted with culturing pathogens for those labs and later began producing them as critical ingredients for infectious disease test developers worldwide.

The company was incorporated and went public on the Toronto Stock Exchange in 1992. In its early years, Microbix focused on building expertise in culturing infectious disease agents and producing antigens for diagnostic test manufacturers. This remains the foundation of the company's business today.

In the 2000s and 2010s, Microbix expanded its product portfolio beyond antigens to include quality assessment products. The QAPs line was developed to address the need for standardized materials that clinical laboratories use to verify the accuracy of their diagnostic tests. This diversified the company's revenue beyond its core antigen business.

A significant chapter in Microbix's history involves urokinase. The drug, originally marketed as Abbokinase, had been used in the United States for over 20 years to treat blood clots. In the late 2000s, Microbix signed a letter of intent with ImaRx Therapeutics to manufacture urokinase and transfer the New Drug Application to Microbix's production facility. Microbix was believed to be the only supplier capable of producing urokinase on a commercial scale at its Toronto facility.

The company rebranded its urokinase product as Kinlytic and pursued FDA re-approval for the US market. In May 2023, Microbix signed an agreement with Sequel Pharma LLC, a specialty pharmaceutical company funded by a private equity firm, to provide approximately C$50 million in funding needed to relaunch Kinlytic. The agreement was dependent on reconfirming prior FDA guidance received in 2017. Positive new guidance was received from the FDA in fall 2023, and Sequel confirmed its commitment with a milestone payment of US$2.0 million in November 2023.

William J. Gastle, the company's founder, passed away on September 6, 2023, in Edmonton, Alberta. He had built Microbix from a small laboratory media supplier into a life sciences company with over 100 employees and a global customer base.

In FY2025, Microbix faced setbacks when two large clients reduced their activity with the company. Antigen sales to its Chinese distributor declined due to fewer respiratory infections, and a QAPs client cancelled test-development programs. These setbacks contributed to the 27% revenue decline and a net loss of C$2.2 million, compared to net income of C$3.5 million in FY2024.

As a small Canadian biotechnology company, Microbix does not publish extensive sustainability reports. The company's primary social contribution is enabling the production of clinical diagnostics that detect infectious diseases and ensuring the accuracy of those tests through its quality assessment products.

Microbix received funding from the Ontario Together Fund and FedDev, government programs designed to support companies contributing to public health preparedness. These grants reflect the strategic importance of domestic diagnostic ingredient manufacturing for Canada's healthcare system.

The company's work on Kinlytic urokinase addresses a clinical need for thrombolytic therapy options. The drug's previous unavailability in the United States created a gap in treatment options for certain blood clot conditions, and Microbix's efforts to restore supply have been supported through partnership funding rather than traditional pharmaceutical development financing.

Microbix faces regulatory oversight typical of companies manufacturing biological products and pursuing drug development. The company's antigen production and quality assessment products are subject to medical device regulations in the markets where they are sold, including FDA regulations in the United States and Health Canada requirements.

The Kinlytic urokinase program requires FDA re-approval through a supplemental Biologics Licensing Application. The company received positive guidance from the FDA in fall 2023, but the approval process is expected to take approximately two to three years from that point. Regulatory delays or requirements for additional clinical data could extend this timeline.

The company's revenue concentration risk has been a source of investor concern. The FY2025 revenue decline of 27% and swing to a net loss of C$2.2 million demonstrated the vulnerability of a small company dependent on a limited number of large clients. The cancellation of programs by a QAPs client and reduced sales to the Chinese distributor highlighted the need for customer diversification.